Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 853 | 700 | 265 | 250 | 314 |
| Marketable Securities | 1,622 | 2,088 | 423 | 478 | 470 |
| Receivables | 3,619 | 4,022 | 14 | 13 | 17 |
| Inventories | 1,469 | 1,176 | 19 | 21 | 7 |
| TOTAL | $7,563 | $7,986 | $720 | $763 | $808 |
| Non-Current Assets | |||||
| PPE Net | 1,708 | 1,786 | 277 | 279 | 288 |
| Investments And Advances | 572 | 282 | 2 | 2 | 12 |
| Other Non-Current Assets | 56 | 63 | 14 | 17 | 20 |
| TOTAL | $2,336 | $2,130 | $293 | $298 | $319 |
| Total Assets | $9,899 | $10,115 | $1,013 | $1,060 | $1,127 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,967 | 3,267 | 7 | 15 | 17 |
| TOTAL | $3,035 | $3,374 | $38 | $47 | $47 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 40 | 42 | 4 | 6 | 9 |
| TOTAL | $71 | $80 | $44 | $44 | $47 |
| Total Liabilities | $3,106 | $3,453 | $82 | $91 | $94 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,426 | 1,426 | 856 | 856 | 856 |
| Common Shares | 10,780 | 10,780 | 6,485 | 6,485 | 6,485 |
| Retained earnings | 1,100 | 761 | -508 | -448 | -381 |
| Other shareholders' equity | -75 | 134 | -33 | -55 | -59 |
| TOTAL | $6,792 | $6,662 | $932 | $970 | $1,033 |
| Total Liabilities And Equity | $9,899 | $10,115 | $1,013 | $1,060 | $1,127 |